The disclosure relates to oxygen scavenging molecules, compositions, methods of making the compositions, articles prepared from the compositions, and methods of making the articles. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The disclosure relates to oxygen scavenging molecules, compositions, methods of making the compositions, articles prepared from the compositions, and methods of making the articles. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to novel methods of preparation of substituted pyridines and the compounds produced therefrom. In particular, the present invention provides efficient methods for the construction of diversely substituted pyridines, with varying substitution patterns under simple and metal-free conditions with high atom- and pot-economy and excellent functional group tolerance, and which are useful for the synthesis of natural products.

The present invention provides sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, their use in the treatment of conditions for which treatment with a dopamine agonist is therapeutically beneficial and pharmaceutical compositions comprising compounds of the invention. Compounds according to the invention are of formula (Id), wherein R1 and R2 are each independently selected from H, and substituent (iii) below, wherein * indicates the attachment point to oxygen, wherein R3 is selected from H and COR4, and wherein R4 is selected from H and C1-C6 alkyl, with the proviso that R1 and R2 cannot both be H,15 or a pharmaceutically acceptable salt thereof.

The present invention provides sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, their use in the treatment of conditions for which treatment with a dopamine agonist is therapeutically beneficial and pharmaceutical compositions comprising compounds of the invention. Compounds according to the invention are of formula (Id), wherein R1 and R2 are each independently selected from H, and substituent (iii) below, wherein * indicates the attachment point to oxygen, wherein R3 is selected from H and COR4, and wherein R4 is selected from H and C1-C6 alkyl, with the proviso that R1 and R2 cannot both be H,15 or a pharmaceutically acceptable salt thereof.

A redox flow battery is described herein that has a sodium-super-ionic-conductor NaSICON barrier disposed between an anolyte chamber of the battery and the catholyte chamber of the battery. The NaSICON barrier prevents crossover of solvents or active redox species between the anolyte chamber and the catholyte chamber, while permitting transport of sodium ions between the chambers. In exemplary embodiments, the anolyte chamber includes an anolyte solution that comprises a first active redox species dissolved in a first solvent, while the catholyte chamber includes a catholyte solution that comprises a second active redox species dissolved in a second solvent.

A redox flow battery is described herein that has a sodium-super-ionic-conductor NaSICON barrier disposed between an anolyte chamber of the battery and the catholyte chamber of the battery. The NaSICON barrier prevents crossover of solvents or active redox species between the anolyte chamber and the catholyte chamber, while permitting transport of sodium ions between the chambers. In exemplary embodiments, the anolyte chamber includes an anolyte solution that comprises a first active redox species dissolved in a first solvent, while the catholyte chamber includes a catholyte solution that comprises a second active redox species dissolved in a second solvent.

The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.

##STR00001##